『Neurology: Disease Deep Dive』のカバーアート

Neurology: Disease Deep Dive

Neurology: Disease Deep Dive

著者： Practical Neurology
無料で聴く

概要
 The field of neurology is vast and complex. This series provides thorough conversations with key expert physicians on neurologic conditions including the evolution of our understanding and treatment of these conditions.2024 Practical Neurology 生物科学 科学
エピソード
  • What's New in Migraine Prevention? Understanding the 2026 AAN/AHS Guidelines

    What's New in Migraine Prevention? Understanding the 2026 AAN/AHS Guidelines
    2026/10/30
    Andrew Blumenfeld, MD, Cedars-Sinai Neurology, Los Angeles, CA, discusses the updated American Academy of Neurology and American Headache Society guideline on preventive migraine therapy, including the growing emphasis on shared decision-making, the role of CGRP-targeted therapies, and balancing efficacy with tolerability. He also examines how clinicians can assess meaningful treatment response beyond migraine frequency and explores emerging approaches to prevention, including combination therapies and novel therapeutic targets. Reference: Potrebic S, Tanveer S, Becker WJ, et al. Pharmacologic Treatment for Migraine Prevention in Adults Practice Guideline Recommendations: Report of the AAN Guidelines Subcommittee and the American Headache Society. Headache. 2026;66(9):2173-2184. doi:10.1111/head.70199
    続きを読む 一部表示
    20 分
  • Rethinking Multiple Sclerosis: A New Biologic Framework for MS Progression

    Rethinking Multiple Sclerosis: A New Biologic Framework for MS Progression
    2026/10/19
    Daniel Ontaneda, MD, PhD, Cleveland Clinic, Cleveland, OH, explains why traditional labels such as relapsing-remitting, secondary progressive, and primary progressive multiple sclerosis (MS) may not fully reflect the underlying biology of the disease and why a more dynamic framework could better capture how MS changes over time.
    続きを読む 一部表示
    23 分
  • Tavapadon Treatment for Early Parkinson Disease: Findings from the TEMPO Trials

    Tavapadon Treatment for Early Parkinson Disease: Findings from the TEMPO Trials
    2026/09/25
    Hubert Fernandez, MD, Cleveland Clinic, Cleveland, OH, discusses findings from the TEMPO trials evaluating tavapadon, a selective dopamine D1/D5 receptor partial agonist, as monotherapy in early Parkinson disease and as an adjunct to levodopa in patients with motor fluctuations. He examines efficacy, tolerability, adverse events, and where tavapadon could fit within the evolving Parkinson disease treatment landscape.
    続きを読む 一部表示
    17 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません